Bio-Rad Laboratories reported third quarter 2026 results that exceeded analyst estimates on both the top and bottom lines. While the Life Science segment continues to navigate academic research and bioprocessing headwinds, currency-neutral growth in Clinical Diagnostics and digital PCR instruments supported overall performance and margin expansion.
Key Highlights
- Non-GAAP EPS of $2.65 beat the $2.61 estimate, while revenue of $656.4 million exceeded the $649.94 million expectation.
- Clinical Diagnostics segment sales rose 2.8% on a currency-neutral basis, driven by increased volume in diabetes products and quality systems.
- Droplet Digital PCR (ddPCR) instrument revenue grew by more than 20%, which helped mitigate a 2.4% currency-neutral decline in the total Life Science segment.
- Non-GAAP operating margin expanded 100 basis points to 12.8%, reflecting initial benefits from transformation and R&D reprioritization initiatives.
- The company reaffirmed its full-year 2026 outlook, continuing to expect currency-neutral revenue growth between -3.0% and +0.5%.